Home
HelpTest ID OVAPA Ovarian Malignancy Risk Assessment, Ova1Plus, Serum
Ordering Guidance
This test is intended for individuals with a detected pelvic mass and supportive evidence suggests surgical management.
Shipping Instructions
1. Specimens sent refrigerated must reach Mayo Clinic Laboratories within 4 days of collection.
2. Specimens sent frozen must be shipped on dry ice.
Specimen Required
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 2 mL Serum
Collection Information:
1. Allow the specimen to clot for at least 30 minutes.
2. Within 2 hours of collection, centrifuge the specimen.
3. For serum gel tubes, aliquot serum into a plastic vial or send centrifuged serum gel tube.
4. For red top tubes, aliquot serum into a plastic vial within 10 minutes of centrifugation.
Useful For
Risk assessment for ovarian malignancy in women who present with an adnexal mass and are indicated for surgical management
Highlights
Ova1Plus is a non-invasive blood test that combines two US Food and Drug Administration-cleared tests (Ova1 [high sensitivity] and Overa [high specificity]) for women with adnexal masses planned for surgery.
Ova1 is a multivariate index assay combining results from five tests: CA-125 II, prealbumin, apolipoprotein A1, beta2-microglobulin, and transferrin into a single-valued index between 0 and 10; a higher value corresponds to a higher risk of malignancy.
Overa is a second-generation multivariate index assay that seeks to improve the specificity of the Ova1 by looking at three markers (CA-125 II, transferrin, and apolipoprotein A1) and two new biomarkers (follicle-stimulating hormone and human epididymis protein 4).
Testing Algorithm
Ova1Plus is comprised of two separate tests, Ova1 and Overa. The Ova1 test is always performed. The Overa test is performed reflexively only when an intermediate risk is determined from Ova1.
For more information see Clinical Triage for Adnexal Masses
Method Name
Immunoassay/Multivariate Index Assay/Electrochemiluminescence Immunoassay (ECLIA)
Reporting Name
Ova1Plus, SSpecimen Type
SerumSpecimen Minimum Volume
Serum: 1.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Refrigerated (preferred) | 8 days |
| Frozen | 90 days |
Reference Values
An interpretive report will be provided.
Day(s) Performed
Monday, Wednesday, Friday
Report Available
5 daysPerforming Laboratory
Aspira Labs, Inc.Test Classification
This test was developed and its performance characteristics determined by Aspira Labs, a wholly owned subsidiary of Aspira Women's Health. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. Before making any treatment decisions, all women should discuss the results with their healthcare provider, who can recommend follow up testing or procedures when appropriate. Ova1 Plus is a reflex process which performs Ova1 and Overa, both independently FDA-cleared tests for women with adnexal masses.CPT Code Information
81503
|
0003U |
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| OVAPA | Ova1Plus, S | Not Provided |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| OVA1P | Ova1Plus | Not Provided |